Reportlinker Adds Competitor Analysis: Targeted Therapy of Diabetes

NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Competitor Analysis: Targeted Therapy of Diabetes

http://www.reportlinker.com/p0483024/Competitor-Analysis-Targeted-Therapy-of-Diabetes.html

Product description

The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV inhibitors, GLP-1 analogs and SGLT inhibitors. Furthermore, emerging approaches for diabetes therapy are reported including glucokinase activators and 11beta-HSD1 inhibitors. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. Competitor projects are listed in a tabular format providing information on:

-Drug Codes,

-Target / Mechanism of Action,

-Class of Compound,

-Company,

-Product Category,

-Indication,

-R&D Stage and

-additional comments with a hyperlink leading to the source of information. 

Insulin

Rec Human Insulin for Injection (2nd Generation)

Biosimilar Rec Human Insulin for Injection (2nd Generation) in

Regulated Markets

Rhu Insulin (2nd Generation) in Off-Patent Countries: China

Rhu Insulin (2nd Generation) in Off-Patent Countries: Russia

Rhu Insulin (2nd Generation) in Off-Patent Countries: India

Rhu Insulin (2nd Generation) in Off-Patent Countries: Others

Modern Insulin Analogs (3rd Generation) for Injection

Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets

Tailored and Novel Insulin Analogs (4th Generation) for

Injection

Human Insulin with Drug Delivery for Injection

Other Long-Acting Insulin for Injection

Transgenic Human Insulin for Injection

Insulin/GLP-1 Combination Products

Inhaled Insulin

Oral Insulin

Transdermal Insulin

Others

PPAR Agonists

PPAR alpha A < p>

PPAR gamma Agonists / Insulin Sensitizer

PPAR alpha and gamma Agonists

PPAR delta Agonists

PPAR delta and gamma Agonists

PPAR alpha and delta Agonists

PPAR pan Agonists (alpha, gamma and delta)

Unspecified PPAR Agonists

Dipeptidyl peptidase-IV (DPP-IV) Inhibitors

GLP-1 Receptor Agonists

GLP-1 Analogs with Daily SC Injections

GLP-1 Analogs with Once Weekly SC Injections

GLP-1 Analogs with Bi-Weekly or Monthly SC Injections

Other GLP-1 Analogs for SC Injections

GLP-1 Analogs in Drug Delivery Formulations/Devices for

Parenteral Administration

GLP-1 Analogs in Drug Delivery Formulations for Oral

Administration

Oral Small Molecule GLP-1 Receptor Agonists

Dual Target GLP-1 Receptor Agonists / Combination Products

GLP-1 Analogs in Other, Non-Diabetes Indications

Sodium-Dependent Glucose Co-Transporter 2 (SGLT-2) Inhibitors

11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors

Glucokinase Activators (GKA)

Other Emerging Diabetes Drugs

Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists

Sirtuin (SIRT) Activators

Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors

Glucagon Receptor (GCGR) Antagonists

Glucocorticoid Receptor (GCGR) Antagonists

Novel Insulin Sensitizers

G-Protein Coupled Receptor 119 (GPR119) Agonists

Other Drugs Augmenting GLP-1 Secretion: GPR40, GPR120 & TGR5 Agonists

Other Glucometabolic Approaches

Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors

Other Metabolic Approaches

FGF-21-Receptor Agonists

Anti-Inflammatory Approaches

Induction of Immune Tolerance

Pancreatic Beta Cell Protection & Regeneration

Pancreatic Islet Cell Transplantation

Various Antidiabetic Approaches

To order this report:

: Competitor Analysis: Targeted Therapy of Diabetes

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker